Diabetes Mellitus

262

Review clinical trials related to Diabetes Mellitus. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Early Tracking of Childhood Health Determinants (ETCHED) Study

Background: Children s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much weight gain during pregnancy also may have long-term effects on the child s health. Children who become overweight or obese during childhood tend to remain so as adults. Researchers want to study many risk factors during and after pregnancy, and how these affect a child s development. They will also follow the mother s health and well-being after pregnancy. Objectives: To learn how a pregnant mother s environment, lifestyle, and health conditions may affect her child s growth and development from birth until adulthood. Eligibility: American Indian/Alaska Native (AI/AN) or Hispanic adult pregnant women and their offspring. Design: Mothers will have 3 visits during pregnancy. In the child s first year, mothers will have 2 visits and their child will have 4. Children will have 2 visits in their second year and 1 each year until they turn 18. Mothers will have a visit 2 years after birth and 4-5 years later. Both the mother and child s medical records will be reviewed. They will have physical exams and give blood and stool samples. Mothers may give cord blood and placenta samples. They will give breastmilk and urine samples. They will fill out questionnaires. They will have an ultrasound. They may get an activity monitor. Mother and child will be followed until the child s 18th birthday. ...

Participants needed: 1,500
Trial details
Age: 1-99Biological sex: AllType: ObservationalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Oct 16, 2026Locations: 1
Eligibility criteria

Pregnant women aged 18 years or older (pregnancy confirmed by urine or serum pre... [+2]

Women who are incarcerated or are unable to consent. [+1]

Status: Recruiting

A Novel Digital Tool Clinicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for clinicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 clinicians, including physicians, physician assistants, or advanced practice registered nurses, from two local hospitals in CT, USA. Clinicians will recruit two patients each (N=48) having CVD risk factors. Clinicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Clinicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for clinicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for clinicians to use to prescribe customized exercise routines for patients with CVD risk factors, and clinicians and patients will be satisfied with P3-EX.

Participants needed: 72
Trial details
Age: 18-64Biological sex: AllType: InterventionalSponsor: University of ConnecticutUpdated: Oct 16, 2026Locations: 3
Eligibility criteria

Do not recommend written exercise programs or plans to all their patients, nor r... [+15]

Status: Recruiting

Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.

Participants needed: 130
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Medtronic VascularUpdated: Oct 16, 2026Locations: 21
Eligibility criteria

Individual is diagnosed with hypertension and has a baseline office systolic blo... [+3]

Individual lacks appropriate renal artery anatomy [+8]

Status: Recruiting

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.

Participants needed: 32
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Oct 15, 2026Locations: 7
Eligibility criteria

Aged ≥18 years [+35]

Pregnant or lactating [+22]

Status: Recruiting

American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)

Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - "CRIC 2018" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.

Participants needed: 504
Trial details
Age: 21-80Biological sex: AllType: ObservationalSponsor: University of New MexicoUpdated: Oct 13, 2026Locations: 3
Eligibility criteria

Glomerular Filtration Rate (GFR): eGFR of =>61<80 and microalbuminuria > 30 or e...

Unable or unwilling to provide informed consent [+11]

Status: Recruiting

The DENOCHARCOT Trial

The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.

Participants needed: 38
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Ole Lander SvendsenUpdated: Oct 13, 2026Locations: 8
Eligibility criteria

Age 18-80 years [+3]

Duration of the acute Charcot foot for more than 3 months (at the screening visi... [+23]

Status: Recruiting

Genetic Studies of Insulin and Diabetes

The study will allow researchers to obtain blood, plasma, DNA, and RNA for genetic studies of insulin. There will be a focus on the causes of insulin resistance and diabetes mellitus. Insulin is a hormone found in the body that controls the level of sugar in the blood. Insulin resistance refers to conditions like diabetes when insulin does not work properly. In this study researchers would like to compare patients with diabetes and other forms of insulin resistance to normal individuals. The study will investigate how insulin attaches to cells. Researchers will take 4 to 6 ounces (100-150 ml) of blood from adult patients and may request up to 12 ounces (one unit) of blood if necessary. Skin samples may be taken for a biopsy if further genetic testing is necessary. In addition some patients may be asked not to eat for up to 72 hours prior to testing.

Participants needed: 1,200
Trial details
Age: 6-120Biological sex: AllType: ObservationalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Oct 8, 2026Locations: 1
Eligibility criteria

Patients with various syndromes of lipodystrophy [+28]

Patients with evidence for insulin resistance or a disorder associated with seve... [+13]

Status: Recruiting

Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and Identification of Its Associated Factors.

Diabetes-related distress is a psychological construct associated with poorer glycaemic control in people living with diabetes. In France, few data are available on this topic and none focus specifically on adults with type 2 diabetes. Diabetes-related distress is not mentioned in the current French national guidelines on the management of type 2 diabetes, whereas international societies such as the ADA and, more recently, the EASD now recommend its regular assessment. This single-centre observational study conducted in the endocrinology department of Nice University Hospital aims to estimate the prevalence of severe diabetes-related distress in adults with type 2 diabetes receiving usual care, and to identify associated clinical, psychosocial and lifestyle factors. Participants complete validated self-report questionnaires (PAID-20 for diabetes distress, WHOQOL-BREF for quality of life, and a modified Starting The Conversation dietary questionnaire), and clinical data are extracted from electronic medical records. The study does not modify usual medical management and participation consists only in completing the questionnaires and receiving feedback on the results.

Participants needed: 290
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Universitaire de NiceUpdated: Oct 7, 2026Locations: 1
Eligibility criteria

Adults (age ≥ 18 years). [+4]

Age < 18 years. [+12]

Status: Recruiting

Effect of Acupressure on Blood Glucose And Anxiety in Elderly With Diabetes

This study aims to evaluate the effects of acupressure on blood glucose levels and anxiety in older adults with diabetes. A three-arm randomized controlled trial will be conducted, comparing acupressure, sham acupressure, and routine care groups. Fasting and postprandial blood glucose levels will be assessed as primary outcomes, and state anxiety will be assessed as a secondary outcome.

Participants needed: 48
Trial details
Age: 65+Biological sex: AllType: InterventionalSponsor: Abant Izzet Baysal UniversityUpdated: Oct 9, 2026Locations: 1
Eligibility criteria

Being 65 years of age or older, [+6]

The presence of open wounds, infections, skin lesions, or anatomical abnormaliti... [+1]

Status: Recruiting

Taining Golden Lake Comprehensive Chronic Disease Management Initiative

This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. The project will systematically collect questionnaires, physical measurements, laboratory tests, imaging data, and biological samples to build a multi-dimensional health database and biobank. Through 3-year follow-up, the study seeks to reveal the epidemiological patterns and risk factors of chronic diseases, characterize the natural course of multimorbidity and aging syndromes, and develop a comprehensive chronic disease management model suitable for rural and mountainous regions.

Participants needed: 20,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: First Affiliated Hospital of Fujian Medical UniversityUpdated: Oct 6, 2026Locations: 1
Eligibility criteria

Age ≥18 years, male or female. [+4]

Refusal to sign informed consent. [+4]

Status: Recruiting

Total Contact Soft Cast in Diabetic Foot Ulcers

To determine the effectiveness, compliance, patient tolerance, ease of use and safety of total contact soft cast in diabetic foot ulcers.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of MinnesotaUpdated: Oct 2, 2026Locations: 1
Eligibility criteria

Allergy to Calamine or Zinc oxide [+5]

Status: Recruiting

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Participants needed: 630
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Novo Nordisk A/SUpdated: Sep 30, 2026Locations: 74
Eligibility criteria

Male or female (sex at birth). [+4]

Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than (<)... [+4]

Status: Not yet recruiting

Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes

This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.

Participants needed: 6,900
Trial details
Age: 22+Biological sex: AllType: InterventionalSponsor: University of Wisconsin, MadisonUpdated: Oct 2, 2026Locations: 1
Eligibility criteria

Clinic must be from a health system with at least two clinics that meet eligibil... [+8]

Have a documented DR screening in the electronic health record within 12 months... [+2]

Status: Not yet recruiting

DiaFootCare to Promote Self-Care of Diabetic Foot Ulcers in Oman

This study aims to evaluate DiaFootCare, a mobile health application designed to support self-care and monitoring among adults with diabetic foot ulcers. The application provides educational and self-care support, medication and care reminders, wound monitoring using standardized foot photographs, and communication of relevant information to support pharmacist-led monitoring. The study will evaluate the usability and effectiveness of DiaFootCare among patients with diabetic foot ulcers receiving care at the National Diabetes and Endocrine Centre in Oman. Participants using DiaFootCare will be compared with participants receiving usual care. The study will assess outcomes related to diabetic foot self-care, medication adherence, glycemic control, wound healing, and participants' use of and engagement with the application.

Participants needed: 139
Trial details
Age: 40-60Biological sex: AllType: InterventionalSponsor: Oman Ministry of HealthUpdated: Sep 29, 2026Locations: 1
Eligibility criteria

- Adults aged 40 to 60 years. [+6]

Severe cognitive, visual, physical, or communication impairment that prevents us... [+3]

Status: Recruiting

Inter-Device Concordance of Plantar Thermal Asymmetry Measurement (HIK-DM-2026)

This cross-sectional observational study measures the inter-device concordance between two infrared thermographic cameras, a low-cost model (HIKMICRO Mini2 V2) and a high-resolution model (HIKMICRO M60), when measuring plantar skin temperature in adults with diabetes mellitus. Each participant undergoes two consecutive thermographic acquisitions, always less than 10 seconds apart, from a fixed tripod at 75 cm, under standardized environmental conditions. The order of the two cameras is randomized 1:1 at participant level (sequence A: M60 then Mini2 V2; sequence B: Mini2 V2 then M60). The primary endpoint is the agreement between the two devices for contralateral thermal asymmetry (Delta T) in each of six pre-specified plantar regions of interest (ROIs), quantified by the intraclass correlation coefficient (ICC) for absolute agreement, with the consistency ICC for mean plantar temperature (Tmean) as an exploratory endpoint. The study is strictly metrological. Neither camera is a medical device under Regulation (EU) 2017/745, no clinical decision is derived from the measurements, and the study does not evaluate the detection, diagnosis, screening or prevention of any disease. Neither device is designated as a diagnostic reference standard. Participants with diabetes mellitus are included solely because plantar thermal variability is greater in this population, which makes the inter-device comparison metrologically demanding.

Participants needed: 130
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Eduardo Luis Martín JavierUpdated: Sep 30, 2026Locations: 1
Eligibility criteria

Age 18 years or older. [+3]

Active ulcers or open wounds in the plantar area, since exudation alters thermal... [+7]

Status: Recruiting

Surveillance of Pancreatic Health After Diabetes Diagnosis

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.

Participants needed: 5,000
Trial details
Age: 50-84Biological sex: AllType: InterventionalSponsor: University Hospital Southampton NHS Foundation TrustUpdated: Sep 28, 2026Locations: 31
Eligibility criteria

50 - 84 years of age at the time of enrolment (within year of birth, not month o... [+4]

Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% o... [+10]

Status: Recruiting

FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)

The goal of this clinical trial is to learn the best combination of family components that yields optimal weight loss among Black adults. The main question it aims to answer is: What combination of four family components in combination with a standard behavioral weight loss program yields optimal weight loss among Black adults? Researchers will compare different combinations of family skills components (communication content, cohesion content, number of sessions, and mode of delivery) to see the best weight loss. Participants will: * Participate in a 6-month behavioral weight loss intervention * Attend core weight loss in-person group sessions, and dyad based family sessions * Keep track of weight, dietary intake and physical activity

Participants needed: 256
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: University of North Carolina, Chapel HillUpdated: Sep 29, 2026Locations: 1
Eligibility criteria

self-identified as Black or African American (Index participant) [+7]

planning to move out of the area with the next 8-9 months [+11]

Status: Recruiting

Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)

Diabetes mellitus is a global problem and regular monitoring of blood sugar control is important to reduce the risk of complications secondary to poor sugar control. To assess control a simple blood test is undertaken called the HbA1c. This test gives an assessment of the person's sugar control over the previous 3 months and needs to be done regularly so that changes can be made to their treatment. The HbA1c test is routinely performed in clinic and blood taken from a vein in the arm using a needle and syringe. This involves travelling to the clinic, taking time off work and expense to the patient. Many times and for the above reasons patients do not attend the clinic and therefore do not have the HbA1c performed. Therefore the clinician will not know how their diabetes is doing and also they will not be able to make changes to the patient's diabetes treatment. In this study we would like to assess home monitoring of diabetes by doing the HbA1c at home and sent to the laboratory. At the same time we will be checking the patient's blood cholesterol (lipids) levels and thyroid function (to assess if the thyroid gland which is in the neck, is making adequate hormones). In the study the patient will first visit the clinic where blood will be taken from the arm as is done in routine clinical care. Then the patient will take blood himself/herself either from the finger (finger prick as is done when a patient checks their own blood glucose) or from the upper arm using a device that will be applied to the skin and blood will be collected in a small tube attached to the device. Half the patients will be asked to do a finger prick test and the other half will do the upper arm skin blood draw. The patient will be asked to fill a questionnaire, this is to understand their experience with the blood self-collection and how they classify it in comparison with the routine clinical care. The patient will then go home with the similar device that they used in the clinic and will be asked to do the same blood draw at home as they did in the clinic (either finger prick or upper arm blood draw). They will need to do this within 2 days of the visit to the clinic. They will then post the sample to the central laboratory in the envelope provided. At the same time the patient will be asked to fill out a questionnaire. This is to understand the ease or difficulty of the testing at home but will also help us analyse the cost effectiveness of doing the home blood collection.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Tameside General HospitalUpdated: Sep 30, 2026Locations: 1
Eligibility criteria

Adult subjects aged 18 years and over at the time of signing the informed consen... [+4]

Aged less than 18 years of age [+2]

Status: Not yet recruiting

Improving Health Literacy on Chronic Kidney Disease Among Diabetics: the Malaysian Nutritional, Emotional and Physical Health Literacy for Optimal Renal Outcome (My-NEPHRO) Trial

The goal of this clinical trial is to learn if a health literacy module via mobile application intervention can improve health outcomes and health literacy in diabetics with chronic kidney disease and could include any of the following: diabetic patients with non-dialysis chronic kidney disease aged more than 18 years old. The main questions it aims to answer are: 1. Are there differences in health literacy between intervention and control group at pre- and post-3 and 6 month exposure to the health literacy module in both intervention and control groups 2. Are there differences in quality of life scores between intervention and control group at pre- and post-3 and 6 month exposure to the health literacy module in both intervention and control groups? 3. Are there differences in renal function(eGFR) and HbA1C in pre- and post- 6 month exposure to the health literacy module between the intervention and control groups? Researchers will compare with normal care to see whether the effect of this intervention is larger than the effect of usual care in improving health literacy and HbA1c level, and impact towards renal disease progression and quality of life in diabetics with chronic kidney disease. Participants will be instructed to access the mobile application weekly.

Participants needed: 102
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Universiti Sultan Zainal AbidinUpdated: Sep 23, 2026
Eligibility criteria

those having comorbid conditions affecting the kidney such as nephrolithiasis [+3]

Status: Recruiting

FEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES

Fear of hypoglycemia has a significant impact on both medication and dietary adherence in individuals with diabetes. Through avoidance behaviors, it can disrupt metabolic control, prevent the achievement of glycemic targets, and increase the risk of long-term complications. Therefore, monitoring only biochemical parameters is insufficient in diabetes management. It is crucial for healthcare professionals to systematically assess the fear of hypoglycemia.

Participants needed: 100
Trial details
Age: 18-65Biological sex: AllType: ObservationalSponsor: Bilecik Seyh Edebali UniversitesiUpdated: Sep 16, 2026Locations: 1Duration: 1 Day
Eligibility criteria

Not listed

Status: Not yet recruiting

Leukocyte Glucose Index and Severity of Diabetic Ketoacidosis

This prospective cohort study aims to evaluate the relationship between admission Leukocyte Glucose Index (LGI) and the severity of diabetic ketoacidosis, as well as the presence of diabetic microvascular complications, among adult patients at Assiut University Hospitals.

Participants needed: 120
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Assiut UniversityUpdated: Sep 16, 2026Duration: 7 Days
Eligibility criteria

- Age 18 years or older [+3]

- Active infection or sepsis judged likely to substantially influence leukocyte... [+7]

Status: Not yet recruiting

Community Physical Exercise Program in Chronic Disease

This study focuses on promoting physical activity (PA) through the implementation of a Community Physical Exercise Program for Chronic Diseases (CPEP-CD), targeting individuals aged 50 years and older with at least two of the following conditions: cardiovascular and/or cerebrovascular disease or risk (CVD), overweight, diabetes mellitus (DM), and musculoskeletal diseases. The primary objective is to improve muscle and cardiorespiratory health and well-being, while also contributing to a more objective and evidence-based exercise prescription for these pathological conditions. Population ageing is a global challenge associated with an increased prevalence of chronic diseases that compromise quality of life (QoL). A sedentary lifestyle is linked to declines in muscle function and cardiorespiratory fitness and is considered a major risk factor for morbidity and mortality. Consequently, physical exercise is widely recommended as a key non-pharmacological intervention across multiple chronic diseases. According to World Health Organization (WHO) guidelines, regular PA is a protective factor in the prevention and management of non-communicable diseases, including cardiovascular and cerebrovascular diseases and DM. In addition, PA provides mental health benefits, supports healthy weight maintenance, and enhances overall well-being. In adults, regular PA is associated with reductions in all-cause mortality, cardiovascular mortality, and the incidence of hypertension. Within this context, the aim of this project is to implement a community-based physical exercise program for individuals with chronic disease and multimorbidity, focusing on CVD and cerebrovascular disease or risk, DM, and OA. The program integrates existing exercise prescription guidelines while personalizing exercise progression according to both disease-specific and multimorbidity profiles. The primary outcomes include improvements in cardiorespiratory fitness, muscular strength, bone health, functional capacity, and QoL. Additionally, through individualized training monitoring, this study seeks to establish an exercise prescription tailored to the most prevalent combinations of chronic diseases, thereby providing more objective and practical guidance for family physicians, exercise professionals, and rehabilitation specialists, and supporting more personalized and targeted exercise-based strategies for chronic disease prevention and management.

Participants needed: 150
Trial details
Age: 50+Biological sex: AllType: InterventionalSponsor: Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do AlgarvUpdated: Sep 10, 2026Locations: 1
Eligibility criteria

Adults aged ≥50 years; [+6]

Moderate to severe cognitive impairment - Montreal Cognitive Assessment (MoCA). [+13]

Status: Recruiting

Impact GLP-1 Agonists Following Bariatric

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariatric surgical procedures have been shown to be effective in treating obesity as well as superior to best medical therapy for treatment of diabetes not just through restriction of calories but also through a positive impact in modifications of gut hormones, changes in circulating bile acids, modifications in the gut microflora as well as other undefined mechanisms. The combined benefits of GLP1-RAs with bariatric surgery have only been studied to a limited effect. In this randomized trial, the effects of continuation or discontinuation of GLP1-RA therapy in patients undergoing bariatric surgery will be determined. We will compare changes in weight, metabolic determinants including circulating bile acids and gut microbiome, psychological determinants of eating behavior, and adverse side effects in patients who continue vs discontinue therapy. Given differences in metabolic and clinical outcomes in patients undergoing vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB), both surgical groups will be examined. The study will be conducted at a high volume bariatric surgical program where patients will undergo randomization at the time of final clinic visit prior to surgery to continue or discontinue GLP1-RA. It is hypothesized that participants who continue GLP1-RA therapy after bariatric surgery will lose more weight with improved blood glucose control than those who discontinue therapy. Furthermore, changes in gut microbiome and circulating bile acids, known determinants of metabolic health, will be modified to a differential extent in those who are on GLP1-RAs vs those where GLP1-RAs are discontinued. Understanding the role these medications play in not only clinical outcomes after metabolic surgery but potential metabolic mechanisms by which surgery improves patient's metabolic health could help people with obesity and type 2 diabetes make informed decisions about their treatment options as well as advise providers on the continuation of these medications in the perioperative and postoperative period.

Participants needed: 150
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: University of Missouri-ColumbiaUpdated: Sep 10, 2026Locations: 1
Eligibility criteria

Greater than 18 years of age [+8]

Pregnant patient [+6]

Status: Not yet recruiting

Effect of Individualized Nursing Care on Diabetes Self-Management

This randomized controlled trial aims to evaluate the effects of individualized nursing care interventions on self-efficacy, empowerment, and self-management behaviors in individuals diagnosed with diabetes. Diabetes requires lifelong management, and standard care approaches often fall short of meeting individual psychosocial and clinical needs. By implementing structured, patient-centered nursing care protocols, this study assesses how personalized education, follow-up, and support mechanisms influence patients' capacity to manage their condition, improve glycemic control, and enhance their overall quality of life.

Participants needed: 68
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of YalovaUpdated: Sep 8, 2026Locations: 1
Eligibility criteria

Diagnosed with diabetes (Type 1 or Type 2) [+3]

Having severe cognitive impairment, psychiatric disorders, or communication barr... [+1]

Status: Recruiting

Changes in Person-reported Outcomes and Behavior Using the Accu-Chek SmartGuide CGM and Predict App

The goal of this controlled pre-post-trial is to test the Accu-Chek SmartGuide continuous glucose monitoring (CGM) system and whether its predictive features provide additional benefits for adults with type 1 diabetes or insulin- treated type 2 diabetes. The main questions this study aims to answer are: * Does using the Accu-Chek SmartGuide together with the Predict App change participants' fear of hypoglycemia? * Does the Predict App affect other psychological and behavioral outcomes, such as sleep quality, confidence in preventing hypoglycemia, diabetes- related distress, and diabetes empowerment? * Does the use of the predictive features affect glucose levels and the way participants use and respond to CGM alarms and trend information? Participants will use the Accu-Chek SmartGuide for 6 weeks. During the first 2 weeks, participants will use the CGM system without the predictive features. During the following 4 weeks, participants will use the system together with the Accu-Chek SmartGuide Predict App. Participants will complete online questionnaires at two time points (after 2 and after 6 weeks) and answer short questions twice a day through a smartphone app during the first 2 weeks and the last 2 weeks of the study. CGM data will be collected throughout the study. A subgroup of 10 participants will also be invited to take part in an online interview about their experiences with the predictive features.

Participants needed: 89
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: FIDAM RDCUpdated: Sep 11, 2026Locations: 1
Eligibility criteria

Type 1 diabetes or Type 2 diabetes with intensified insulin therapy (defined as... [+4]

Use of the SmartGuide CGM solution [+6]